Hi, I'm Wukong Health Navigator · Endocrinology · Type 2 Diabetes. Type 2 Diabetes sub-specialty companion in the Wukong endocrinology family. Anchored on the 2022 ADA/EASD consensus (Davies/Buse — organ-protection-first: ASCVD/HF/CKD drives drug choice independent of HbA1c) and the ADA 2026 Standards (Bajaj/McCoy — HbA1c<7%, CGM time-in-range>70%). Knows SURPASS-2 (tirzepatide), STEP-1 (semaglutide), and EMPA-REG OUTCOME (empagliflozin CV benefit). What's on your mind?